Author Archives: Bruno Quinney

Obese man measures his waist
#Korea #Obesity

Scientists discover hidden molecular switch that fuels obesity 

A research team from Chonnam National University Medical School, Republic of Korea, discovered a new role of Ret finger protein (RFP) in driving fat cell formation and metabolism.  They found that mice lacking RFP resisted weight gain and had better metabolic profile even on a high-fat diet— highlighting… Read More

#News

#AI #Allergen immunotherapy #Allergy #Alzheimer's #Biotech #China #Clinical trial #Eli Lilly #Obesity #Osteoarthritis #Spinogenix

This week in Drug Discovery (8 – 12 December) 

News round-up for 8 – 12 December by Bruno Quinney, Content Team at DDW.  This week in DDW, innovative treatments have been developed for neurodegenerative diseases, allergies and arthritis. Elsewhere, China is becoming the dominant force in the biotech sector.  The top stories:   … Read More

#News

Novartis head office
#AI #Drug discovery #Novartis

Relation and Novartis to advance atopic disease therapeutics 

UK biopharmaceutical company Relation has partnered with Novartis to advance therapeutics for atopic diseases.  The collaboration will pair Relation’s AI-powered drug discovery platform and human data generation capabilities with Novartis’s expertise in immuno-dermatology to identify, validate, and advance potential first-in-class targets in atopic diseases driven by immune dysregulation.  Under the terms of the agreement, Relation will… Read More

#Business & Investment #News

Scientist in laboratory
#ASH 2025 #Clinical trial #Graft vs Host Disease

MaaT013 shows strong survival rate in aGvHD patients 

New results reveal MaaT013 (Xervyteg) achieved a one-year overall survival rate of 54% for the treatment of patients with refractory severe acute Graft-versus-Host Disease (aGvHD).  The data was announced by biotechnology company MaaT Pharma at the American Society of Hematology (ASH) Annual Meeting and Exposition, currently taking place in Orlando, US. Read More

#News

Acute lymphoblastic leukemia
#ASH 2025 #Clinical trial #Leukaemia #Oncology

Pirtobrutinib more effective than ibrutinib, study finds 

A study into treatments for chronic lymphocytic leukaemia and small lymphocytic leukaemia (CLL/SLL) has found that Jaypirca (pirtobrutinib) is more effective than Imbruvica (ibrutinib).  The Phase III, first-of-its-kind BRUIN CLL-314 trial found that pirtobrutinib met its primary endpoint of non-inferiority on overall response rate (ORR) compared to ibrutinib. Pirtobrutinib, developed by Eli… Read More

#Cancer Research #News

Chronic myeloid leukaemia
#ASH 2025 #Leukaemia #Oncology

Drug shows ‘unprecedented’ response in chronic myeloid leukaemia 

Oncology company Terns Pharmaceuticals has announced encouraging results showing its candidate could be a best-in-class treatment for relapsed and refractory chronic myeloid leukaemia (CML).   The Phase I trial of TERN-701 showed a 64% major molecular response (MMR) achievement rate across all efficacy evaluable patients, also proving its safe and… Read More

#Cancer Research #News

Knee pain
#Arthritis #Osteoarthritis #University of Oxford

Gum cells show potential as cure for knee arthritis 

The world’s first patient has been treated for knee osteoarthritis (OA) using gum cells from a human donor.  The patient was treated at Oxford University Hospitals, UK using Allogenic Gingival Fibroblast (aGF) Therapy, a treatment developed by biotechnology startup Scarcell Therapeutics.  The therapy is designed to prevent… Read More

#News

Pills
#Alzheimer's #Clinical trial #Spinogenix

Once-a-day pill could reverse cognitive decline, trial shows 

A new once-a-day pill could reverse cognitive decline in Alzheimer’s patients, a clinical trial has shown.  Tazbentetol, developed by biopharmaceutical company Spinogenix, demonstrated rapid, sustained cognitive improvement in a Phase IIa trial. The randomised, double-blind, placebo-controlled trial enrolled 24 patients in Australia, with Tazbentetol proving to be a safe and effective drug with cognitive… Read More

#News

Chinese flag
#AI #Antibody drug conjugate (ADC) #Biotech #China #ICON

China becoming dominant force in biotech sector, survey says 

China is emerging as a ‘global innovation powerhouse’, according to clinical research organisation ICON.  ICON’s global biotech sector survey, capturing insights from more than 260 biotech professionals and venture capital executives, found that China is cementing its dominance in the sector and Western biotechs must adapt to maintain competitiveness.  According to the survey, funding remains a key challenge, with… Read More

#Business & Investment #News

Myeloma cells
#Arcellx #ASH 2025 #Myeloma

Anito-cel could be ‘significant’ treatment for myeloma 

Biotechnology company Arcellx has announced positive data from the Phase II study of anitocabtagene autoleucel (anito-cel) in patients with relapsed or refractory multiple myeloma (RRMM).  Results from the iMMagine-1 study demonstrate deep and durable responses with a predictable and manageable safety profile in a fourth-line or higher (4L+) RRMM population,… Read More

#Cancer Research #News

Diffuse large B-cell lymphoma
#Advanced Therapies #Cancer research #CAR T-cell therapy #Lymphoma #Miltenyi Biotec

CAR-T therapy could treat large B-cell lymphoma 

Biotechnology company Miltenyi Biotec has announced encouraging results from its CAR-T therapy for patients with second-line, relapsed or refractory large B-cell lymphoma.  Primary analysis of candidate zamtocabtagene autoleucel (zamto-cel) showed the therapy demonstrated significant and clinically meaningful superiority over chemoimmunotherapy. The candidate was evaluated in the DALY 2-EU trial, conducted… Read More

#Cancer Research #News

Haematology
#ASH 2025 #Sanofi #Systemic mastocytosis

Ayvakit is safe long-term treatment for systemic mastocytosis 

New results show Ayvakit (avapritinib) is an effective and safe long-term treatment for systemic mastocytosis (SM).  The data, announced by Sanofi company Blueprint Medicines, showed Ayvakit led to sustained symptom and quality-of-life benefits in indolent SM (ISM) after a median follow-up of more than three years, and extended survival rates in… Read More

#News

Peanut butter
#Allergen immunotherapy #Allergy #Clinical trial

Immunotherapy could treat nut allergies, results show 

A new immunotherapy could treat patients with nut allergies, preliminary results show.  VLP Peanut, an immunotherapy developed by biotechnology company Allergy Therapeutics, reached its primary endpoint in the Phase I/IIa PROTECT trial, with results showing the immunotherapy was safe and well-tolerated. The treatment was evaluated in 48 patients, with a… Read More

#News

#ABPI #Alzheimer's #Clinical trial #Metabolomics #National Institute for Health and Care Excellence (NICE) #Neurodegenerative disorders #Peptides #UK government #US government

DDW Highlights: 9 December 2025

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, a trade agreement between the UK and the US promised to support… Read More

#Podcasts

#Advanced Therapies #Cell and gene therapy #GlobalData #Investment

Investment shifting in cell and gene therapy, report reveals 

Tighter budgets and company acquisitions have altered investment in the cell and gene therapy (CGT) sector, new analysis finds.  According to a report from data and analytics company GlobalData, the CGT sector is transitioning as companies navigate a more selective and strategy-driven funding landscape.  While venture capital (VC) investment in CGTs… Read More

#Business & Investment #News

Vaccine
#Africa #University of Oxford #Vaccines

Oxford’s Lassa fever vaccine administered in trial 

The first volunteer has been dosed in a first-in-human trial of the Lassa vaccine, marking an unprecedented step towards treating Lassa fever.  The vaccine, developed by the University of Oxford, is being assessed for its safety and the immune response it triggers in volunteers. Thirty-one people aged… Read More

#News